"What" Series
What is a sham in clinical trials?
17 January 2024
2 min read
In clinical trials, a sham is a procedure or device that looks the same and feels the same as an active treatment being tested but doesn’t actually do anything. It’s used as a control to compare the effectiveness of the active treatment with no treatment at all.
A placebo, on the other hand, is a dummy pill or other inactive substance that looks the same and feels the same as the active treatment being tested but has no therapeutic effect. It’s used to determine if any observed effects are due to the specific active ingredient(s) in the drug, rather than just the psychological effects of taking a pill.
The sham and placebo are different concept.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Keep Reading
Back to all blogs →
Latest Hotspot
3 min read
Ariceum Therapeutics has applied for a UK Clinical Trial Authorization to start testing its new Iodine-123 labeled PARP inhibitor in recurrent glioblastoma patients
17 January 2024
Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.
"What" Series
2 min read
What's clinical adverse event and it's classification？
17 January 2024
Clinical adverse events (AEs) are any unintended or harmful signs, symptoms, or conditions linked in time to the use of a medical product, regardless of causality.
Latest Hotspot
3 min read
EU Sanctions KRAZATI (adagrasib) as a Selective Therapy for Advanced NSCLC Sufferers Exhibiting KRAS G12C Alteration
16 January 2024
Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).
DrugDeal Decode
4 min read
Exploring the Latest TSLP monoclonal antibody Deal by Aiolos Bio: A Guide to Rapidly Accessing Transaction Insights
16 January 2024
GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.